Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Single Agent Sorafenib in the Treatment of Relapsed Esophageal/Gastric Adenocarcinoma in Platinum Pre-Treated Patients

NCT01158287 is registered in ClinicalTrials.gov with Cancer Trials Ireland as lead sponsor.

NCT NCT01158287
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01158287 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Single Agent Sorafenib in the Treatment of Relapsed Esophageal/Gastric Adenocarcinoma in Platinum Pre-Treated Patients
Lead sponsor
Cancer Trials Ireland
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2009
Completion date
Not reported
Enrollment
54 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, gastric cancer